27 reviews

Elravie Re2O

Particulated human-derived dermal matrix (hADM) · 1.0 mL prefilled syringe · Humedix, South Korea. Extracellular-matrix skin booster for skin density and elasticity.

hADMHuman dermal matrix
1.0 mLPrefilled syringe
3 sessionsCourse in the trial
HumedixManufacturer
SKU: 08087
In Stock

Original price was: $479.00.Current price is: $399.90.
You save

Volume pricing
1 – 4 $479.00 base price
5 – 9 $398.90 16.7 % off
10 – 19 $395.90 17.3 % off
20+ $393.90 17.8 % off
  • Elravie Re2O is a skin booster from Humedix made of purified, particulated human-derived dermal matrix, supplied as a 1.0 mL prefilled syringe.
In Stock
Purchase & earn 20 Points!
Quantity Discount Price
1 - 4 — $399.90
5 - 9 0.25% $398.90
10 - 19 1% $395.90
20+ 1.5% $393.90
Add to Wishlist
Add to Wishlist

Professional use only. This product is intended for administration by licensed healthcare practitioners trained in the relevant anatomy and injection technique. By ordering you confirm you are authorised to purchase and handle products of this class in your jurisdiction. Availability and permitted use vary by country — please verify local regulations before ordering.

Did you like this product? Add to favorites now and follow the product.

Add to Wishlist
Add to Wishlist
Have a Question? Ask a Specialist

(+82) 10 7364 7998 Send a message on WhatsApp.

Low Prices

Price match guarantee

Guaranteed Shipment.

Always the correct part

In-House Experts.

We know our products

Easy Returns.

Quick & Hassle Free

Product overview

Elravie Re2O: a human-derived extracellular-matrix skin booster

Elravie Re2O (also written RE20) is a skin booster from Humedix in South Korea. Its active ingredient is a purified, particulated human-derived dermal matrix (hADM) — the collagen-rich extracellular matrix of human skin, processed to remove cells and fat — supplied as a 1.0 mL prefilled syringe. Our listing gives the strength as 150 mg.

This is a different kind of skin booster from the hyaluronic acid and polynucleotide products most clinics stock. Rather than hydrating the dermis or signalling the skin to repair, it delivers matrix material intended to act as a structural scaffold. Humedix describes it as the first product of its kind in Korea, and it has been available in Korean clinics since late 2024.

Unlike most skin boosters, Elravie Re2O has been studied in a registered clinical trial. A Yonsei University split-face study of 20 adults, followed for 20 weeks, compared Re2O combined with hyaluronic acid against hyaluronic acid alone. Patients receive three intradermal sessions one month apart in the trial protocol, a simple course to explain and schedule.

Matrix, not just hydration

A particulated human-derived dermal matrix intended to act as a structural scaffold in the dermis.

Registered clinical trial

A Yonsei University split-face study (NCT07155278) tested Re2O with hyaluronic acid against hyaluronic acid alone.

Three-session course

The trial protocol used three intradermal injections one month apart, with follow-up at 20 weeks.

Ready-to-use syringe

A 1.0 mL prefilled syringe, so there is no mixing.

Session 1 Baseline treatment
+1 month Session 2
+1 month Session 3
20 weeks Follow-up point in the published trial
Key features

Why practitioners stock Elravie Re2O

Published, registered clinical data

A split-face trial reported in the International Journal of Molecular Sciences (2026) found greater improvement in skin density, volume, elasticity and wrinkle depth on the Re2O side, with no serious adverse events.

A different mechanism from HA or PN boosters

It adds a structural matrix rather than hydration or a repair signal, which gives a clinic a distinct option for patients who have not been satisfied with standard boosters.

A defined protocol

The trial used three intradermal injections one month apart, which is a simple course to explain and schedule.

Premium positioning

A higher-priced product for patients who want an advanced option and understand what it is.

Indications & Treatment Areas

Treatment areas and indications

Areas and concerns where extracellular-matrix boosters are used. All are skin-quality indications.

Loss of skin density

Skin that has lost density and elasticity, where a structural approach is preferred to hydration alone. The published trial treated the cheeks.

Fine wrinkles and texture

Fine wrinkles and uneven texture, in patients who understand that the response is gradual.

Neck and other thin-skinned areas

Areas showing loss of density, treated by practitioners trained for the site. Delicate sites such as the under-eye need specific training.

A note on scope

Elravie Re2O is an injectable human-derived product. Which indications are permitted, how it is classified and what training is required are set by the regulatory framework where you practise. Korea Filler Experts supplies the product. Nothing here is a recommendation to treat any medical condition.

Composition

Elravie Re2O specification

Active component Particulated human-derived dermal matrix (hADM), purified
Type Extracellular-matrix (ECM) skin booster
Strength (listing) 150 mg — confirm on carton
Presentation 1.0 mL prefilled syringe
Route Intradermal
Course in the published trial 3 injections, 1 month apart
Manufacturer Humedix Co, Ltd, South Korea
SKU 08087

Before you order

  • Check the lot number and expiry on the carton against the syringe.
  • We do not dispatch stock with under 6 months of shelf life remaining unless agreed in advance.
  • Store as stated on the carton. Do not freeze.
  • Check local rules. Human-derived products can be restricted or unauthorised. Confirm what you may import and use where you practise.
  • Request the manufacturer’s documentation for your records before you treat.

Tiered pricing applies from 5 units.

What each component does

What hADM is

The skin’s extracellular matrix is the framework of collagen, elastin and other molecules that supports its cells. Elravie Re2O is made from human dermal tissue that has been processed to remove cells and fat, leaving the matrix, which is then ground into micro-particles for injection. Humedix describes the process as designed to remove the components that trigger an immune response.

What the clinical evidence shows

Registered trial NCT07155278 (Yonsei University) enrolled 20 adults. Each patient received Re2O combined with hyaluronic acid on one cheek and hyaluronic acid alone on the other, as three intradermal injections one month apart, with follow-up for 20 weeks. The published report in the International Journal of Molecular Sciences (2026) states that the Re2O side showed greater improvement in skin density, volume, elasticity and wrinkle depth, and that no serious adverse events were observed.

This is a single small split-face study sponsored by a university, so it is encouraging rather than conclusive. The comparator was hyaluronic acid, not a polynucleotide or another booster.

Human-derived material: what to consider

  • Informed consent. Patients should know the product is of human origin. Some patients will decline it for personal, ethical or religious reasons.
  • Donor screening and traceability. The manufacturer’s documentation on donor screening and processing is the authority. Keep batch records.
  • Regulation. Human-derived products may be regulated as human tissue or biologics rather than as cosmetic injectables. One report states that the product does not yet have authorisation for commercial use in the United States. Confirm what applies where you practise.
Mechanism of action

How it works

01
How the matrix is described

The extracellular matrix is the collagen-rich framework that supports the skin’s cells. Humedix describes Elravie Re2O as delivering purified matrix particles into the dermis, where they act as a structural scaffold that supports the skin’s own cellular activity.

The supporting evidence is a single small split-face study. Describe results to patients as gradual and variable, not guaranteed.

How to use

How Elravie Re2O is used

Reference information for trained practitioners. The manufacturer’s prescribing information and local clinical protocols take precedence over this page.

Step by step

  1. Assess and consent

    Confirm the aim is skin density and quality. Explain that the product is of human origin and obtain explicit consent. Review medical history, autoimmune disease, allergies and medication.

  2. Prepare the skin

    Remove make-up and cleanse thoroughly. Apply topical anaesthetic if required.

  3. Check the syringe

    Inspect the syringe, seal and expiry. Record the lot number against the patient’s record.

  4. Inject intradermally

    Prepare aseptically and inject using the technique and depth in the manufacturer’s information. Because the product targets structural layers, placement strongly affects the outcome.

  5. Plan the course

    The published trial used three injections one month apart. Follow the manufacturer’s instructions and review the response before and after the course.

  6. Aftercare

    Advise sun protection, no make-up for the period set by your protocol, and avoidance of saunas and strenuous exercise for 48 hours.

Administration notes

Be open about the evidence. The supporting data come from one small split-face study. Describe results as gradual and variable, and do not promise a specific change in density or wrinkle depth.

Keep full records. Record the lot number and the patient’s consent to a human-derived product for each treatment.

  • Single use. One syringe, one patient. Discard any remainder.
  • Do not inject into infected, inflamed or broken skin.
  • Dispose of needles into a sharps container in line with local clinical waste rules.

After treatment

  • Redness, swelling, tenderness and bruising at the injection points are common and settle within days
  • Small lumps may be felt at the points for a period
  • Avoid strenuous exercise, saunas and steam rooms for 48 hours
  • Seek review for severe pain, spreading redness, fever or a lump that grows or becomes tender
Storage & handling

Storing and handling Elravie Re2O

Storage

Store as stated on the carton and in the manufacturer’s insert, away from direct sunlight. Do not freeze.

Before use

Keep the syringe in its original sterile packaging until use. Check the seal and expiry.

After opening

Single patient, single session. Discard after treatment.

Handling and shipping note

Do not use if the packaging is damaged, the sterile seal is broken or the expiry date has passed. Dispose of used syringes and needles as clinical waste in line with local requirements.

In the box

What's included with Elravie Re2O

1 × Elravie Re2O syringe 1.0 mL, prefilled
Original Humedix carton With lot number and expiry date
Manufacturer insert As supplied with the product
Protective packaging Secure transit packaging
Lot and expiry confirmation Available before dispatch on request
Tracked shipping Tracking number issued on dispatch

Check the carton for any needles included. Topical anaesthetic is not supplied. Plan three syringes per patient for a full course.

FAQ

Elravie Re2O — frequently asked questions

What is Elravie Re2O?

A skin booster from Humedix whose active ingredient is a purified, particulated human-derived dermal matrix (hADM), supplied as a 1.0 mL prefilled syringe. Our listing gives the strength as 150 mg.

How is it different from a normal skin booster?

Most boosters hydrate the dermis with hyaluronic acid or signal repair with a polynucleotide. Elravie Re2O delivers matrix material intended to act as a structural scaffold in the dermis.

Is there clinical evidence?

Yes, a limited amount. A registered Yonsei University split-face trial (NCT07155278) of 20 adults compared Re2O with hyaluronic acid against hyaluronic acid alone, using three injections one month apart and 20 weeks of follow-up. The published report found greater improvement in skin density, volume, elasticity and wrinkle depth on the Re2O side and no serious adverse events. It is a single small study.

Is it made from human tissue?

Yes. It is made from human dermal tissue that has been processed to remove cells and fat. Patients should be told this and give consent, and you should keep lot records.

How many sessions are needed?

The published trial used three injections one month apart. Follow the manufacturer’s instructions and review the response.

Does one session work?

We cannot say that. The trial protocol used three sessions, and we do not promise a result after a single treatment.

Is it approved?

It has been available in Korean clinics since late 2024. One report states that it does not yet have authorisation for commercial use in the United States. Human-derived products can be regulated as human tissue or biologics, so confirm what applies where you practise.

What are the risks?

Redness, swelling, tenderness, bruising and lumps at the injection points are the most common. As with any injectable, infection and hypersensitivity are possible. The manufacturer’s information lists the full warnings.

Who can buy and use this product?

Injectable products are for administration by licensed healthcare practitioners. We supply qualified professionals and do not sell to consumers.